FGF6 inhibits oral squamous cell carcinoma progression by regulating PI3K/AKT and MAPK pathways
Scientific Reports · 2024
DOI: 10.1038/s41598-024-78552-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Reports, 2024. Verfasst von Xuan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Basic Medicine, The Affiliated Stomatological Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Mouth Neoplasms, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Program of Sichuan Province, The Key Program of Applied Basic Research of Southwest Medical University.
Abstract (Originalsprache)
To explore diagnostic and prognostic biomarkers in the progression of oral squamous cell carcinoma (OSCC) and to reveal their regulatory mechanisms in key pathways. A RayBiotech protein chip was used to screen differentially expressed serum proteins in OSCC, oral leukoplakia (OLK), and healthy participants. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were used to determine the pathways enriched by characteristic differential proteins. Immunohistochemical analysis and western blotting were used to verify the expression of characteristic differential proteins and key regulatory factors in human tissues and in a nude mouse model. Fibroblast growth factor 6 (FGF6) was identified as a key differential protein and was weakly expressed in OSCC tissues. The mitogen-activated protein kinases (MAPK) and PI3K-AKT pathways were identified as key signaling pathways. The results showed that pERK, Cyclin D1, pAKT, and BCL2 were highly expressed in OSCC, Caspase9 was lowly expressed in OSCC. With an increase in FGF6 expression in nude mice, the expression of FGFR4, pERK, Cyclin D1, pAKT, BCL2, GPX4, and ACSL4 increased, and the expression of Caspase9 decreased. FGF6 may change the expression of apoptosis-related proteins and proliferation factors by binding to FGFR4 in the PI3K-AKT/MAPK pathway and may inhibit the ferroptosis of OSCC, thereby possibly participating in the process of inhibiting OSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Basic Medicine, The Affiliated Stomatological Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.
- Oral & Maxillofacial Reconstruction and Regeneration of Luzhou Key Laboratory, Southwest Medical University, Sichuan, 646000, China.
- Department of Periodontics & Oral Mucosal Diseases, The Affiliated Stomatological Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.
- Department of Stomatology Technology, School of Medical Technology, Sichuan College of Traditional Medcine, Mianyang, 621000, China.
- Department of Orthodontics, Mianyang Stomatological Hospital, Mianyang, 621000, China.
- Oral & Maxillofacial Reconstruction and Regeneration of Luzhou Key Laboratory, Southwest Medical University, Sichuan, 646000, China. nieminhaiwork@163.com.
Förderung
- Science and Technology Program of Sichuan Province
- The Key Program of Applied Basic Research of Southwest Medical University
Zitieren
APA
Zhang, X., Xu, Y., Shi, L., Chen, X., Hu, M., Zhang, M., Nie, M., & Liu, X. (2024). FGF6 inhibits oral squamous cell carcinoma progression by regulating PI3K/AKT and MAPK pathways. Scientific Reports. https://doi.org/10.1038/s41598-024-78552-7
Vancouver
Zhang X, Xu Y, Shi L, Chen X, Hu M, Zhang M, et al. FGF6 inhibits oral squamous cell carcinoma progression by regulating PI3K/AKT and MAPK pathways. Scientific Reports. 2024. doi:10.1038/s41598-024-78552-7
BibTeX
@article{Zhang2024,
author = {Zhang, Xuan and Xu, Yingjiao and Shi, Lijuan and Chen, Xiao and Hu, Miaoling and Zhang, Mengxue and Nie, Minhai and Liu, Xuqian},
title = {FGF6 inhibits oral squamous cell carcinoma progression by regulating PI3K/AKT and MAPK pathways},
journal = {Scientific Reports},
year = {2024},
doi = {10.1038/s41598-024-78552-7}
}
EUVIMED